MUK Nine b: OPTIMUM Treatment Protocol
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
MUK Nine b: OPTIMUM Treatment Protocol is a clinical trial[1].
Key Facts
- MUK Nine b: OPTIMUM Treatment Protocol is in the country of OPTIMUM Treatment Protocol — country (P17): United Kingdom[2].
- MUK Nine b: OPTIMUM Treatment Protocol's instance of is recorded as OPTIMUM Treatment Protocol — instance of (P31): clinical trial[3].
- MUK Nine b: OPTIMUM Treatment Protocol's start time is recorded as +2017-09-28T00:00:00Z[4].
- MUK Nine b: OPTIMUM Treatment Protocol's end time is recorded as +2020-10-01T00:00:00Z[5].
- MUK Nine b: OPTIMUM Treatment Protocol's main subject is recorded as OPTIMUM Treatment Protocol — main subject (P921): multiple myeloma[6].
- MUK Nine b: OPTIMUM Treatment Protocol's number of participants is recorded as {'unit': '1', 'amount': '+95'}[7].
- MUK Nine b: OPTIMUM Treatment Protocol's title is recorded as MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.[8].
- MUK Nine b: OPTIMUM Treatment Protocol's short name is recorded as MUKnineb[9].
- MUK Nine b: OPTIMUM Treatment Protocol's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
- MUK Nine b: OPTIMUM Treatment Protocol's ClinicalTrials.gov ID is recorded as NCT03188172[11].
- MUK Nine b: OPTIMUM Treatment Protocol's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+100'}[12].
- MUK Nine b: OPTIMUM Treatment Protocol's research intervention is recorded as OPTIMUM Treatment Protocol — research intervention (P4844): (RS)-lenalidomide[13].
- MUK Nine b: OPTIMUM Treatment Protocol's research intervention is recorded as OPTIMUM Treatment Protocol — research intervention (P4844): melphalan[14].
- MUK Nine b: OPTIMUM Treatment Protocol's research intervention is recorded as OPTIMUM Treatment Protocol — research intervention (P4844): daratumumab[15].
- MUK Nine b: OPTIMUM Treatment Protocol's research intervention is recorded as OPTIMUM Treatment Protocol — research intervention (P4844): (RS)-cyclophosphamide[16].
- MUK Nine b: OPTIMUM Treatment Protocol's clinical trial phase is recorded as OPTIMUM Treatment Protocol — clinical trial phase (P6099): phase II clinical trial[17].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): The Queen Elizabeth Hospital[18].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Birmingham Heartlands Development Corporation[19].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Beatson Institute for Cancer Research[20].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Manchester Royal Infirmary[21].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): The Christie NHS Foundation Trust[22].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Churchill Hospital[23].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Southampton General Hospital[24].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Ninewells Hospital[25].
- MUK Nine b: OPTIMUM Treatment Protocol's research site is recorded as OPTIMUM Treatment Protocol — research site (P6153): Derriford Hospital[26].